{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:50:24Z","timestamp":1758441024095,"version":"3.44.0"},"reference-count":6,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,3,1]],"date-time":"2020-03-01T00:00:00Z","timestamp":1583020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2020,3]]},"DOI":"10.1016\/j.mayocp.2019.12.010","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T08:14:43Z","timestamp":1583136883000},"page":"615","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Reply \u2014 Immune Checkpoint Inhibitor\u2013Induced Type 1 Diabetes: An Underestimated Risk"],"prefix":"10.1016","volume":"95","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7067-173X","authenticated-orcid":false,"given":"Julian A.","family":"Marin-Acevedo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razvan M.","family":"Chirila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5345-2268","authenticated-orcid":false,"given":"Roxana","family":"Dronca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.mayocp.2019.12.010_bib1","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.mayocp.2019.12.009","article-title":"Immune checkpoint inhibitor induced type 1 diabetes: an underestimated risk","volume":"95","author":"Akturk","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2019.12.010_bib2","article-title":"A\u00a0systematic review of cases of diabetes mellitus following Immune checkpoint inhibitor therapy for cancer","volume":"67","author":"Mizokamin Stout","year":"2018","journal-title":"Diabetes"},{"issue":"1","key":"10.1016\/j.mayocp.2019.12.010_bib3","doi-asserted-by":"crossref","first-page":"e000591","DOI":"10.1136\/bmjdrc-2018-000591","article-title":"Immune checkpoint inhibitors: an emerging cause of insulin-dependent diabetes","volume":"7","author":"Kotwal","year":"2019","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"12","key":"10.1016\/j.mayocp.2019.12.010_bib4","doi-asserted-by":"crossref","first-page":"e150","DOI":"10.2337\/dc18-1465","article-title":"Increased Reporting of Immune Checkpoint Inhibitor-Associated Diabetes","volume":"41","author":"Wright","year":"2018","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.mayocp.2019.12.010_bib5","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1111\/dme.14050","article-title":"Immune checkpoint inhibitor-induced Type 1 diabetes: a systematic review and meta-analysis","volume":"36","author":"Akturk","year":"2019","journal-title":"Diabet Med"},{"issue":"03","key":"10.1016\/j.mayocp.2019.12.010_bib6","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/a-0843-3366","article-title":"A\u00a0systematic review and meta-analysis of endocrine-related adverse events associated with immune checkpoint inhibitors","volume":"51","author":"de Filette","year":"2019","journal-title":"Hormone and Metabolic Research"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619310845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619619310845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:33:56Z","timestamp":1758418436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619619310845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3]]},"references-count":6,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,3]]}},"alternative-id":["S0025619619310845"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.12.010","relation":{},"ISSN":["0025-6196"],"issn-type":[{"type":"print","value":"0025-6196"}],"subject":[],"published":{"date-parts":[[2020,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Reply \u2014 Immune Checkpoint Inhibitor\u2013Induced Type 1 Diabetes: An Underestimated Risk","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.03.012","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2019.12.009","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}